Efficacy and Safety of Sildenafil for Treating the Patients With Congenital Heart Disease Combining Severe Pulmonary Hypertension in Plateau Area
10.3969/j.issn.1000-3614.2014.09.012
- VernacularTitle:西地那非治疗高原地区先天性心脏病合并重度肺动脉高压的疗效和安全性探讨
- Author:
Yanliang XIA
;
Ruhai MA
;
Hong CHEN
- Publication Type:Journal Article
- Keywords:
Sildenaifl;
Plateau;
Congenital heart disease;
Severe pulmonary hypertension
- From:
Chinese Circulation Journal
2014;(9):702-705
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the efifcacy and safety of sildenaifl for treating the patients of congenital heart disease (CHD) with severe pulmonary hypertension in plateau area.
Methods: A total of 50 CHD patients combining severe pulmonary hypertension treated in our hospital from 2010-01 to 2013-10 were studied. The patients were randomly divided into 2 groups, n=25 in each group. Control group, the patients received conventional treatment and Sildenaifl group, based on conventional treatment, the patients received additional sildenaifl medication. The hemodynamic, blood gas, routine and biochemistry were recorded and compared between 2 groups.
Results: Compared with Control group, Sildenaifl group had more reduction of pulmonary artery pressure, increased arterial pressure of oxygen, left ventricular output, cardiac index and oxygenation index, all P<0.05. The patients’ arterial pressure, blood routine and biochemistry were similar between 2 groups, P>0.05. There was no obvious adverse reaction observed in Sildenaifl group.
Conclusion: Based on conventional treatment, Sildenafil may effectively reduce the pulmonary artery pressure in CHD patients combining pulmonary hypertension in plateau area, it improving the cardiac function without adverse reaction.
